GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Winddown Corp (OTCPK:PLXPQ) » Definitions » Cyclically Adjusted Price-to-FCF

PLx Pharma Winddown (PLx Pharma Winddown) Cyclically Adjusted Price-to-FCF : (As of May. 07, 2024)


View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Winddown Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


PLx Pharma Winddown Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for PLx Pharma Winddown's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PLx Pharma Winddown Cyclically Adjusted Price-to-FCF Chart

PLx Pharma Winddown Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PLx Pharma Winddown Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PLx Pharma Winddown's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, PLx Pharma Winddown's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PLx Pharma Winddown's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PLx Pharma Winddown's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where PLx Pharma Winddown's Cyclically Adjusted Price-to-FCF falls into.



PLx Pharma Winddown Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

PLx Pharma Winddown's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2022 is calculated as:

For example, PLx Pharma Winddown's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2022 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=-0.384/125.2265*125.2265
=-0.384

Current CPI (Sep. 2022) = 125.2265.

PLx Pharma Winddown Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201212 0.000 96.871 0.000
201303 -0.480 98.209 -0.612
201306 -0.419 98.518 -0.533
201309 -1.414 98.790 -1.792
201312 -0.844 98.326 -1.075
201403 -3.131 99.695 -3.933
201406 -3.207 100.560 -3.994
201409 -2.578 100.428 -3.215
201412 -2.670 99.070 -3.375
201503 -2.845 99.621 -3.576
201506 -2.974 100.684 -3.699
201509 -3.419 100.392 -4.265
201512 -3.081 99.792 -3.866
201603 -3.937 100.470 -4.907
201606 0.899 101.688 1.107
201609 -0.062 101.861 -0.076
201612 -0.092 101.863 -0.113
201703 -0.502 102.862 -0.611
201706 -0.620 103.349 -0.751
201709 -0.205 104.136 -0.247
201712 -0.690 104.011 -0.831
201803 -0.457 105.290 -0.544
201806 -0.286 106.317 -0.337
201809 -0.159 106.507 -0.187
201812 -0.262 105.998 -0.310
201903 -0.375 107.251 -0.438
201906 -0.296 108.070 -0.343
201909 -0.368 108.329 -0.425
201912 -0.411 108.420 -0.475
202003 -0.410 108.902 -0.471
202006 -0.309 108.767 -0.356
202009 -0.341 109.815 -0.389
202012 -0.221 109.897 -0.252
202103 -0.262 111.754 -0.294
202106 -0.232 114.631 -0.253
202109 -0.334 115.734 -0.361
202112 -0.485 117.630 -0.516
202203 -0.613 121.301 -0.633
202206 -0.654 125.017 -0.655
202209 -0.384 125.227 -0.384

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


PLx Pharma Winddown  (OTCPK:PLXPQ) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


PLx Pharma Winddown Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of PLx Pharma Winddown's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


PLx Pharma Winddown (PLx Pharma Winddown) Business Description

Traded in Other Exchanges
N/A
Address
8 The Green, Suite 11895, Dover, DE, USA, 19901
PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.
Executives
Rita M O'connor officer: Chief Financial Officer 4 OAK PARKWAY, SPARTA NJ 07871
Natasha Giordano director, officer: Chief Executive Officer 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael J Valentino director, officer: Executive Chairman 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
John Hadden director 1375 S FORT HARRISON AVE, CLEARWATER FL 33756
Robert D. Hardie 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Molly G. Hardie 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Level One Partners, Llc 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Kirk K Calhoun director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Gary S. Balkema director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Robert Casale director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Anthony Bartsh director C/O PARK WEST ASSET MANAGEMENT, LLC, 900 LARKSPUR CIRCLE, SUITE 165, LARKSPUR CA 94939
Park West Asset Management Llc 10 percent owner 1 LETTERMAN DRIVE, SUITE C5-900, SAN FRANCISCO CA 94129
Efthymios Deliargyris officer: Chief Medical Officer C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Gary L Mossman officer: Chief Operating Officer 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
David Emerson Jorden officer: Acting Chief Financial Officer 2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381